Expression and clinical value of p53, CD117 and CD44v5 in thymus epithelial tumor

Résumé fourni par la source

Objective To investigate the expression of p53, CD117 and CD44v5 in thymus epithelial tumor and their correlation with clinicopathological features and prognosis of thymus epithelial tumor in combining with WHO classification and Masaoka stage. Methods The immunohistochemical expression of p53, CD117 and CD44v5 in tissues from 104 resected thymus epithelial tumors with different types and stages and 10 normal thymuses by tissue microarray. The correlation between the expression of the proteins and the clinicopathological features or prognosis was analyzed. Results Of 104 thymus epithelial tumors,38.2% were positive for p53, 15.7% positive for CD117 and 57.8% positive for CD44v5 respectively.All 10 normal thymuses were not positive for the three proteins. There was significant difference in the expression of p53, CD117 and CD44v5 p53 among WHO histological classifications ( P ＜ 0. 05 ). The expression of p53 and CD44v5 showed significant difference among Masaoka stages (P ＜ 0. 05). The positive expression rate of CD117 (60. 0%) and CD44v5 ( 100. 0% ) was significantly increased in thymic carcinoma. COX regression multivariate analysis indicated that the increased CD117 expression and Masaoka staging were significant independent prognostic factors. Conclusion p53, CD117 and CD44v5 are useful immunohistochemical markers for the diagnosis of thymus epithelial tumor, and the examination of CD117 and CD44v5 would greatly help in the differential diagnosis of thymic carcinoma from thymoma. The expression of p53 and CD44v5 in thymus epithelial tumor can predict its invasive capacity. Key words: Thymus epithelial tumor; p53; CD117; CD44v5

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.